CrossBridge Bio, Inc., a pre-clinical biotechnology company pioneering the development of next-generation dual-payload antibody-drug conjugates (ADCs) announces a definitive agreement to be acquired by Eli Lilly and Company (“Lilly”). CrossBridge Bio, a Houston-based biotechnology firm founded in 2023, is developing a new dual-payload ADC technology originally created by Kyoji Tsuchikama at the University of Texas Health Science Center at Houston (UTHealth Houston). Under the terms of the agreement, Lilly will acquire CrossBridge Bio, and CrossBridge Bio shareholders could receive up to $300 million in cash, inclusive of an upfront payment and a subsequent payment upon achieving a specified development milestone.
Read the full article: CrossBridge Bio Enters an Agreement to Be Acquired by Eli Lilly to Advance Next-Generation Dual-Payload Antibody-Drug Conjugates //
Source: https://www.businesswire.com/news/home/20260414133394/en/CrossBridge-Bio-Enters-an-Agreement-to-be-Acquired-by-Eli-Lilly-to-Advance-Next-Generation-Dual-Payload-Antibody-Drug-Conjugates